We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Partners With Dunad Therapeutics to Develop Protein Degradation Therapies
Novartis Partners With Dunad Therapeutics to Develop Protein Degradation Therapies
Novartis has teamed up with Cambridge, UK-based Dunad Therapeutics to develop protein degradation therapies in a deal potentially worth more than $1.3 billion.